NovoCure (NVCR) Stock Is Trending Overnight — Here's What You Should Know
Neutral
0.0
NovoCure Ltd (NASDAQ:NVCR) shares are trending on Thursday.
Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved Optune Pax for the treatment of locally advanced pancreatic cancer.
First Approval In Three Decades
The approval marks the first new treatment for locally advanced pancreatic cancer in nearly 30 years, according to the company’s announcement.
Optune Pax, which is a portable therapeutic device that delivers Tumor Treating Fields (TTFields) noninvasively through wearable arrays, is approved for use with gemcitabine and nab-paclitaxel chemotherapy.
Frank Leonard, Novocure's CEO, said, “This is a proud moment for Novocure and we look forward to bringing Optune Pax to patients and the healthcare pr
Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved Optune Pax for the treatment of locally advanced pancreatic cancer.
First Approval In Three Decades
The approval marks the first new treatment for locally advanced pancreatic cancer in nearly 30 years, according to the company’s announcement.
Optune Pax, which is a portable therapeutic device that delivers Tumor Treating Fields (TTFields) noninvasively through wearable arrays, is approved for use with gemcitabine and nab-paclitaxel chemotherapy.
Frank Leonard, Novocure's CEO, said, “This is a proud moment for Novocure and we look forward to bringing Optune Pax to patients and the healthcare pr
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
